BHCM
CATX icon

Brevan Howard Capital Management’s Perspective Therapeutics CATX Stock Holding History

Brevan Howard Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,899
Closed -$46.4K – 1093
2024
Q1 		$46.4K Buy
+3,899
New +$33.2K ﹤0.01% 941

Other funds holding CATX

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brevan Howard Capital Management's CATX Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of Perspective Therapeutics (CATX) in Q2 2024, closing a stake of 3,899 shares — an estimated $46.4K sold.

Brevan Howard Capital Management first reported a position in CATX in Q1 2024 and held it in 1 quarter. The position peaked at $46.4K in Q1 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining Perspective Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 3,899 Perspective Therapeutics shares in Q2 2024, an estimated $46.4K.
  • Brevan Howard Capital Management first reported a position in Perspective Therapeutics in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's Perspective Therapeutics position peaked at $46.4K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.